ZYME vs. RNA, ACAD, GPCR, RYTM, TGTX, BHC, INDV, JANX, DCPH, and MRVI
Should you be buying Zymeworks stock or one of its competitors? The main competitors of Zymeworks include Avidity Biosciences (RNA), ACADIA Pharmaceuticals (ACAD), Structure Therapeutics (GPCR), Rhythm Pharmaceuticals (RYTM), TG Therapeutics (TGTX), Bausch Health Companies (BHC), Indivior (INDV), Janux Therapeutics (JANX), Deciphera Pharmaceuticals (DCPH), and Maravai LifeSciences (MRVI). These companies are all part of the "pharmaceutical preparations" industry.
Avidity Biosciences (NASDAQ:RNA) and Zymeworks (NYSE:ZYME) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, dividends, profitability, valuation, earnings, community ranking, risk and institutional ownership.
Avidity Biosciences has a beta of 0.81, suggesting that its share price is 19% less volatile than the S&P 500. Comparatively, Zymeworks has a beta of 1.18, suggesting that its share price is 18% more volatile than the S&P 500.
Zymeworks received 149 more outperform votes than Avidity Biosciences when rated by MarketBeat users. Likewise, 68.42% of users gave Zymeworks an outperform vote while only 64.62% of users gave Avidity Biosciences an outperform vote.
In the previous week, Avidity Biosciences had 4 more articles in the media than Zymeworks. MarketBeat recorded 8 mentions for Avidity Biosciences and 4 mentions for Zymeworks. Zymeworks' average media sentiment score of 0.93 beat Avidity Biosciences' score of 0.15 indicating that Avidity Biosciences is being referred to more favorably in the media.
Zymeworks has a net margin of -249.63% compared to Zymeworks' net margin of -2,103.78%. Avidity Biosciences' return on equity of -28.37% beat Zymeworks' return on equity.
92.9% of Zymeworks shares are owned by institutional investors. 3.7% of Avidity Biosciences shares are owned by company insiders. Comparatively, 1.2% of Zymeworks shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Avidity Biosciences currently has a consensus price target of $41.33, indicating a potential upside of 55.39%. Zymeworks has a consensus price target of $12.67, indicating a potential upside of 39.65%. Given Zymeworks' stronger consensus rating and higher possible upside, equities analysts clearly believe Avidity Biosciences is more favorable than Zymeworks.
Zymeworks has higher revenue and earnings than Avidity Biosciences. Avidity Biosciences is trading at a lower price-to-earnings ratio than Zymeworks, indicating that it is currently the more affordable of the two stocks.
Summary
Zymeworks beats Avidity Biosciences on 11 of the 18 factors compared between the two stocks.
Get Zymeworks News Delivered to You Automatically
Sign up to receive the latest news and ratings for ZYME and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ZYME and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Zymeworks Competitors List
Related Companies and Tools
